Abstract
Patients with immune-mediated inflammatory diseases on anti-tumor necrosis factor (TNF) agents are at increased risk of developing active tuberculosis (TB). Screening and treatment of latent tuberculosis infection (LTBI) with the use of a standard screening protocol is important in reducing the risk of TB reactivation during therapies with anti-TNF agents. The Latent Tuberculosis Infection Working Group under the Tuberculosis Control Coordinating Committee of the Department of Health and the Hospital Authority has reviewed and assessed local and international scientific evidence and formulated guideline statements on the management of LTBI in patients initiating anti-TNF biologics.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
